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Abstract
Background: Metastasis is the main factor responsible for death in breast cancer patients. Matrix
metalloproteinases (MMPs) and their inhibitors, known as tissue inhibitors of MMPs (TIMPs), and the membrane-
associated MMP inhibitor (RECK), are essential for the metastatic process. We have previously shown a positive
correlation between MMPs and their inhibitors expression during breast cancer progression; however, the
molecular mechanisms underlying this coordinate regulation remain unknown. In this report, we investigated
whether TGF-b1 could be a common regulator for MMPs, TIMPs and RECK in human breast cancer cell models.
Methods: The mRNA expression levels of TGF-b isoforms and their receptors were analyzed by qRT-PCR in a panel
of five human breast cancer cell lines displaying different degrees of invasiveness and metastatic potential. The
highly invasive MDA-MB-231 cell line was treated with different concentrations of recombinant TGF-b1 and also
with pharmacological inhibitors of p38 MAPK and ERK1/2. The migratory and invasive potential of these treated
cells were examined in vitro by transwell assays.
Results: In general, TGF-b2, TbRI and TbRII are over-expressed in more aggressive cells, except for TbRI, which was
also highly expressed in ZR-75-1 cells. In addition, TGF-b1-treated MDA-MB-231 cells presented significantly
increased mRNA expression of MMP-2, MMP-9, MMP-14, TIMP-2 and RECK. TGF-b1 also increased TIMP-2, MMP-2
and MMP-9 protein levels but downregulated RECK expression. Furthermore, we analyzed the involvement of p38
MAPK and ERK1/2, representing two well established Smad-independent pathways, in the proposed mechanism.
Inhibition of p38MAPK blocked TGF-b1-increased mRNA expression of all MMPs and MMP inhibitors analyzed, and
prevented TGF-b1 upregulation of TIMP-2 and MMP-2 proteins. Moreover, ERK1/2 inhibition increased RECK and
prevented the TGF-b1 induction of pro-MMP-9 and TIMP-2 proteins. TGF-b1-enhanced migration and invasion
capacities were blocked by p38MAPK, ERK1/2 and MMP inhibitors.
Conclusion: Altogether, our results support that TGF-b1 modulates the mRNA and protein levels of MMPs (MMP-2
and MMP-9) as much as their inhibitors (TIMP-2 and RECK). Therefore, this cytokine plays a crucial role in breast
cancer progression by modulating key elements of ECM homeostasis control. Thus, although the complexity of this
signaling network, TGF-b1 still remains a promising target for breast cancer treatment.
Background
Breast cancer is a worldwide health problem for women,
since it is the first in incidence and the second in mor-
tality among cancer types [1]. Similarly to the majority
of solid tumors, the main death factor attributed to
breast cancer is the process of cell spreading
(metastasis) from primary tumor to secondary sites [2].
The metastatic process involves a complex cascade of
events, including the organized breakdown of the extra-
cellular matrix (ECM) [3-5]. Matrix metalloproteinases
(MMPs) and their specific inhibitors, known as tissue
inhibitors of MMPs (TIMPs) and the membrane-asso-
ciated MMP inhibitor (RECK), are essential regulators
of ECM degradation [6-9].
The MMPs constitute a large family of endopepti-
dases, which are responsible for degrading almost all
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ECM components, with each ECM element being
cleaved by a specific MMP or a set of MMPs [10]. Con-
sistent with their role in tumor progression, high levels
of several MMP family members have been shown to
correlate with poor prognosis [11,12]. Among the sev-
eral MMPs previously related to breast cancer progres-
sion, the gelatinases (MMP-2 and MMP-9) stand out for
their collagen type IV specific degradation capacity, in
view of the fact that it is an abundant ECM component
[13,14]. In association with TIMP-2, MMP-14 is
involved in MMP-2 activation, being also correlated
with breast cancer progression [15]. Given that ECM
proteolysis is related to important physiological and
pathological processes, homeostasis of the ECM degra-
dation is tightly controlled by the balance between
MMPs and MMP inhibitors [6-9].
Together, the secreted tissue inhibitors of MMPs
(TIMPs) are able to reversibly inhibit the activity of all
MMPs family members. Although first described as
anti-invasive molecules, high levels of TIMP-1, TIMP-2
and TIMP-4 [12,16,17] have been associated to adverse
prognostic and cellular aggressiveness in breast tumors.
This apparently controversial expression profile of
TIMPs could be the result of their recently described
role as multifunctional molecules [8]. The membrane-
associated MMP inhibitor, RECK (reversion-inducing
cysteine-rich protein with Kazal motifs), is able to sup-
press tumor invasion and metastasis by negatively regu-
lating MMP-2, MMP-9 and MMP-14 [9,18,19]. As
reviewed by Noda and Takahashi [19], RECK is
described as a good prognosis marker, and several prior
reports have demonstrated that RECK expression is
decreased during cancer progression [9,19]. However, its
role in breast cancer remains unclear, since no func-
tional analysis of the RECK gene is yet available for this
model. Moreover, unlike other cancer types, previous
results from our laboratory showed that RECK tran-
script levels are higher in highly invasive and metastatic
cell lines compared to less aggressive breast cell lines
[12].
We have previously shown a significantly positive cor-
relation between the mRNA expression levels of MMPs,
TIMPs and RECK, both in cell line models as well as in
tumor tissue samples [12], suggesting that the expres-
sion of these molecules, at least at the transcriptional
level, may be regulated by common factors and signaling
pathways in breast cancer. Like that of MMPs and their
inhibitors, a high expression of TGF-b1 (Transforming
growth factor-b 1) has been positively correlated with
metastasis and tumor aggressiveness in mammary mod-
els [11]. Because TGF-b1 has been shown to be involved
in mechanisms regulating the expression and activity of
some MMPs and/or MMP inhibitors in different mod-
els, [20-28], this cytokine seemed to be an interesting
candidate to be tested as a common modulator of both
types of molecules.
TGF-b is a multifunctional cytokine, which modulates
a wide variety of biological processes, including cell
growth, differentiation, apoptosis, immunity, extracellular
matrix production, angiogenesis, migration and invasion
[29,30]. However, TGF-b may induce entirely different
cellular responses, depending on the cell type and stimu-
lation context, both under physiological and pathological
conditions [29,31]. Similarly, the role of TGF-b in cancer
progression has been shown to be multifaceted, given
that this cytokine acts as a potent growth inhibitor, as an
inducer of EMT (epithelial-mesenchymal transition) as
well as a metastasis inducer, depending on the tumor
stage [32-34]. TGF-b isoforms (TGF-b1, TGF-b2 and
TGF-b3) signal after binding to their transmembrane ser-
ine/threonine kinase receptor type II (TbRII), followed by
association and trans-phosphorylation of TGF-b receptor
type I (TbRI). In addition to the classical TGF-b-induced
signal transduction by Smads, it is well known that this
cytokine also signals in a Smad-independent manner, by
induction of other pathways, such as the extracellular sig-
nal-regulated kinase 1/2 (ERK1/2) and the p38 MAP
kinase (p38 MAPK) [35]. Previous reports have shown
the direct function of these MAPK pathways in signal
transduction of TGF-b-modulated cellular migration and
invasion [21,35].
In the present study, we investigated the role of TGF-
b1 as a common regulator for MMPs, TIMPs and RECK
in highly invasive human breast cancer cells and the
involvement of the ERK1/2 and p38 MAPK pathways in
this mechanism.
Methods
Reagents
The recombinant TGF-b1 and the neutralizing antibody
anti-TGF-b1 were from R&D Systems (Minneapolis,
MN, USA). Antibodies against MMP-14 (113-5B7),
TIMP-1 (7-6 C), TIMP-2 (67-4H11) and T1MP-3 (136-
13H4) were purchased from Merck (Darmstadt, Ger-
many). Antibodies against p-ERK1/2, GAPDH and b-
Tubulin were obtained from Santa Cruz (Santa Cruz,
CA, USA). The antibodies against p-p38 MAPK, total
ERK1/2, total p38 MAPK and RECK were purchased
from Cell Signaling (Beverly, MA, USA). The pharmaco-
logical inhibitors against p38 MAPK (SB203680) and
ERK1/2 (PD98059) were obtained from Tocris
Bioscience (Bristol, UK). The broad-spectrum MMP
inhibitor (GM6001) was purchased from Millipore (Bill-
erica, MA, USA).
Cell lines and culture conditions
Five human breast cancer cell lines displaying different
degrees of invasiveness and metastatic potential were
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used in this study [12]. The MCF-7 and Hs578T cell
lines were maintained in phenol red-free Dulbecco’s
Modified Eagle Medium (LGC Biotecnologia, Cotia, Bra-
zil) supplemented with fetal bovine serum (Cultilab,
Campinas, Brazil) to a final concentration of 10%. The
ZR-75-1, MDA-MB-231 and MDA-MB-435 were cul-
tured in RPMI medium without phenol red (LGC Bio-
tecnologia) supplemented with 10% fetal bovine serum.
For MMPs and MMP inhibitors mRNA analysis by
qRT-PCR, total RNA was extracted when these cells
achieved 80-90% confluence. For TGF-b1 treatment, the
MDA-MB-231 cells were plated in serum-containing
medium and then serum-starved in a final concentration
of 0.1% overnight prior to treatment with TGF-b1 (10
ng/mL). In the “loss of function” study these cells were
treated with different concentration of anti-TGF-b1
antibody, being that the range of tested concentrations
(1, 10, 25 or 50 ng/mL) include those recommended by
the manufacturer. The ERK1/2 or p38 MAPKs inhibi-
tors were added 1 h prior to TGF-b1 treatment. The
MDA-MB-231 cells were treated with TGF-b1 for 20 h.
Quantitative RT-PCR studies
Total RNA from cell lines cultured and treated as
described above was extracted using the RNAspin Mini
Kit (GE Healthcare, Waukesha, WI, USA). For cDNA
synthesis, 1 μg of total RNA was reverse-transcribed
using oligo-dT primers and the Superscript Amplifica-
tion System (Life Technologies, Carlsbad, CA, USA).
Quantitative RT-PCR was carried out using SYBR Green
PCR Master Mix (Life Technologies). Table 1 shows the
primers used, with the optimal concentration (in the
range of 100 nM to 600 nM). The cycling conditions
were 50°C for 2 min, 95°C for 10 min, followed by 40
cycles of 95°C for 15 s and 60°C for 30 s. The mRNA
expression levels of GAPDH, HPRT and H-MBS genes
were subjected to the GeNorm computational program
analysis [36]. The HPRT and H-MBS transcriptional
expression levels, classified as the two most stable genes
according to GeNorm analysis, were used to calculate
the GeNorm Normalization Factor used as the endogen-
ous control for the qRT-PCR. The amplification effi-
ciency analyzed was calculated for each gene from the
given slope in a linear regression curve of Ct values ver-
sus log of cDNA concentration. The corresponding PCR
efficiency (E) of one cycle in the exponential phase was
calculated according to the equation: E = 10[-1/slope].
Relative expression levels were calculated according to
the Pfaffl model [37].
Western blotting
Cultures were washed with ice-cold PBS and then lysed
with lysis buffer (50 mM Tris, pH 7.5; 300 mM NaCl
and 5 mM EDTA, pH 8.0) supplemented with 1×
protease inhibitor mix (GE Healthcare). For protein
phosphorylation analysis, a phosphatase inhibitor mix
(GE Healthcare) was also added. The homogenate was
centrifuged for 30 min at 12,000 × g and the superna-
tant fraction was then collected and stored at -70°C.
Conditioned medium was concentrated using Centricon
Centrifugal Filters (Millipore). The total protein content
for each sample was quantified using a Bio-Rad kit (Bio-
Rad, Hercules, CA, USA). Equal amounts (50-100 μg) of
proteins from each extract were boiled in Laemmli’s
sample buffer containing 5% b-mercaptoethanol for
denaturation. The protein samples were fractionated by
SDS-PAGE and then electro-transferred to nitrocellulose
membranes, which were blocked and then incubated for
2 h at room temperature or overnight at 4°C, depending
on the antibody. Immunoreactive proteins were detected
with an appropriate secondary horseradish peroxidase-
coupled antibody (Vector, Burlingame, CA, USA) and
Table 1 Sequence of primers used
Gene Oligonucleotide sequence (5’-3’)
MMP-2 F: AGCTCCCGGAAAAGATTGATG
R: CAGGGTGCTGGCTGAGTAGAT
MMP-9 F: CACGCACGACGTCTTCCA
R: AAGCGGTCCTGGCAGAAAT
MMP-14 F: GCAGAAGTTTTACGGCTTGCA
R: TCGAACATTGGCCTTGATCTC
TIMP-1 F: CCGCAGCGAGGAGTTTCTC
R: GAGCTAAGCTCAGGCTGTTCCA
TIMP-2 F: CGACATTTATGGCAACCCTATCA
R: GGGCCGTGTAGATAAACTCTATATCC
TIMP-3 F: ATCACCTGGGTTGTAACTGCAA
R: CGCTCCAGAGACACTCGTTCTT
RECK F: TGCAAGCAGGCATCTTCAAA
R: ACCGAGCCCATTTCATTTCTG
TGF-b1 F: GGCCCTGCCCCTACATTT
R: CCGGGTTATGCTGGTTGTACA
TGF-b2 F: TCAAGAGGGATCTAGGGTGGAA
R: GGCARGCTCCAGCACAGAA
TGF-b3 F: CAGCTCTAAGCGGAATGAGCAG
R: TATAGCGCTGTTTGGCAATGTG
TbRI F: AAGTCATCACCTGGCCTTGGT
R: TGCGGTTGTGGCAGATATAGAC
TbRII F: AATATCCTCTGAAGAACGACCTAA
R: TCCCACCTGCCCACTGTTA
PAI-1 F: GGCTGACTTCACGCGTCTTTCAG
R: GTTCACCTCGATCTTCACTTTCTG
GAPDH F: ACCCACTCCTCCACCTTTGA
R: CTGTTGCTGTAGCCAAATTCGT
H-MBS F: TGGACCTGGTTGTTCACTCCTT
R: CAACAGCATCATGAGGGTTTTC
HPRT F: TCATTATGCTGAGGATTTGGAAAG
R: GGCCTCCCATCTCCTTCATC
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visualized using ECL Western blot reagent (GE Health-
care). Quantitative densitometry of the electrophoretic
bands images was carried out with the ImageQuant 5.2
software (GE Healthcare).
Gelatin zymaography assays
Gelatin zymography of conditioned medium was used to
observe the levels of MMP-2 and MMP-9 produced by
MDA-MB-231 cell lines treated with TGF-b1 and/or
MAPK inhibitors. These samples were separated in a
10% SDS-polyacrylamide gel electrophoresis co-polymer-
ized with the enzyme substrate, 0.1% denatured type I
collagen (gelatin type A, Sigma, St. Louis, MO, USA),
[38]. After eletrophoresis, the gels were washed at room
temperature with 2.5% Triton X-100 in water for 1 h
under orbital shaking. The washed gels were incubated
for 48 h at 37°C in substrate buffer containing 50 mM
Tris buffer (pH 8.5) and 10 mM CaCl2 and then stained
with Coomassie Blue R-250 (Sigma) and destained with
40% Methanol (Merck), 10% Acetic Acid (Merck) in
water. Gelatinolytic activity was visualized as negative
staining bands, the image was inverted and the intensity
of each band was normalized to the number of cells.
Each independent experiment was performed in
duplicate.
Migration and invasion assays
1 × 104 MDA-MB-231 cells were plated in the top
chambers of 8 μm pore transwells (BD, Franklin Lakes,
NJ, USA) in a low serum medium and pre-treated for 1
h with PD98059, SB203680 or GM6001. After this per-
iod of pre-treatment the medium at the bottom cham-
ber was supplemented with 10 ng/mL of TGF-b1. These
cells were allowed to migrate towards medium con-
tained this cytokine over a period of 8 h. To assess the
invasive potential of this cell line, the same protocol as
above described was used with matrigel-coated trans-
wells (BD Biosciences). In the invasion assays the cells
were allowed to invade for 24 h. Upon this period of
time, cells at the top chamber were removed and the
cells at the bottom of the filter were stained and fixed
with Coomassie Blue 0.125% in methanol: acetic acid:
H2O (45:10:45, v/v/v) for 15 min. The number of cells
per filter was counted on images from Nikon micro-
scope using 10× objective lens. Duplicate wells were
used per condition in each independent experiment.
Statistical analysis
All statistical analyses were performed using the Graph-
Pad Prism 5.0 program. Results are presented as mean ±
standard deviation. Statistical significance was deter-
mined using the nonparametric KrusKal-Wallis test and
the Dunns post test. Statistically significant differences
were considered when p < 0.05. One way ANOVA
variance analysis and Tukey-Kramer test were employed
to calculate p-values in migration and invasion assays.
Results
Aggressiveness of breast cancer cell lines correlates with
the expression levels of the MMPs and their inhibitors
and with the TGF-b isoforms and receptors
Previous results from our laboratory indicated a positive
correlation between high mRNA expression levels of
MMPs and their inhibitors with breast cancer progres-
sion, both in cellular models and in tumor tissue sam-
ples, with all five human breast cancer cell lines
displaying different invasive and metastatic potential
when maintained in culture for 3 or 5 days [12]. Since
these cell lines display distinct growth rates upon the
same time in culture, they end up achieving different
confluence levels. Bachmeier and collaborators demon-
strated that MMPs and MMP inhibitors are differentially
expressed at distinct cellular densities [39]. This report
showed that the mRNA expression levels of MMP-2,
MMP-9, TIMP-1 and TIMP-2 are modulated by the
percentage of cell confluence in the breast cancer cell
lines, including MCF-7 and MDA-MB-231 [39]. For this
reason, we first analyzed the mRNA expression levels of
MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, TIMP-3
and RECK, in the same panel of five human breast can-
cer cell lines, but now maintained in culture until
achieving 80-90% confluence. The relative mRNA
expression levels of MMP-2, MMP-14, TIMP-1, TIMP-
2, TIMP-3 and RECK were, in general, higher in highly
invasive and metastatic cell lines (MDA-MB-231, MDA-
MB-435 and Hs578T), when compared to less aggressive
ones (MCF-7 and ZR-75-1) (Figure 1). The mRNA
expression levels of MMP-2 were significantly elevated
(p < 0.05) in the MDA-MB-435 and in the Hs578T (p <
0.001) breast cancer cell lines relative to MCF-7 cells.
Similarly, MMP-14 mRNA was significantly overex-
pressed in highly aggressive cells, such as MDA-MB-231
(p < 0.05) and Hs578T (p < 0.01) cells. The most inva-
sive and metastatic cell line, Hs578T, displayed signifi-
cantly higher mRNA expression levels of TIMP-1 (p <
0.001) and TIMP-3 (p < 0.001) than the MCF-7 cell
line. The expression of TIMP-2 was significantly higher
(p < 0.01) in the most aggressive cell lines MDA-MB-
435 and Hs578T, when compared with the least invasive
one (MCF-7). Unlike other MMPs and MMP inhibitors,
the expression profile of MMP-9 presented an opposite
pattern since its transcriptional levels were significantly
lower (p < 0.05) in MDA-MB-435 cells as compared to
MCF-7 (Figure 1).
In order to analyze whether TGF-b could act as a
common regulator of MMPs, TIMPs and RECK in
human breast cancer cell models, we investigated
whether these cellular models express key members of
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the TGF-b network. Thus, we analyzed the mRNA
expression levels of TGF-b isoforms (TGF-b1, TGF-b2
and TGF-b3) and their receptors (TbRI and TbRII) by
qRT-PCR in this panel of five human breast cancer cell
lines in cultures that had reached the same confluence
level (Figure 2). Our results demonstrate that TGF-b2 is
significantly overexpressed in MDA-MB-231 (p < 0.01)
and Hs579T (p < 0.001) cell lines relative to MCF-7.
Similarly, the TGF-b receptors, TbRI and TbRII, were
highly expressed in the most aggressive cell line Hs578T
(p < 0.001 and p < 0.05, respectively). In contrast, the
mRNA levels of TGF-b3 were significantly lower (p <
0.01) in the highly invasive MDA-MB-231 cell line rela-
tive to the least aggressive one (MCF-7). The TGF-b1
transcriptional level was lower (p < 0.05) in ZR-75-1
cells than in MCF-7. Thus, these TGF-b pathway
Figure 1 Relative mRNA expression levels of MMPs and MMPs inhibitors in breast cancer cell lines. Total RNA from a panel of five
human breast cancer cell lines displaying different invasion and metastatic potentials were used to analyze the mRNA expression levels of MMPs
(MMP-2, MMP-9 and MMP-14) and MMPs inhibitors (TIMP-1, TIMP-2, TIMP-3 and RECK) by qRT-PCR. Results are presented as means ± standard
errors from three independent experiments, each measured in triplicate. *, p < 0.05, **, p < 0.01 and *** p < 0.001, all versus control (MCF-7).
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members are expressed by the cell lines included in this
human breast cancer cell panel. These data also suggest
that, following the same tendency as that of MMPs,
TIMPs and RECK, the transcriptional levels of some
TGF-b isoforms and receptors are partially correlated
with cellular aggressiveness.
TGF-b1 induces coordinate expression of MMP-2, MMP-9
and TIMP-2 in MDA-MB-231 breast cancer cells, but
inhibits RECK protein expression levels
Cancer cells with different aggressiveness respond to
TGF-b1 treatment in distinct ways. In general, this cyto-
kine plays a role as an invasion, EMT and metastasis
inducer in advanced tumors [40,41]. Thus, in order to
analyze the role of TGF-b1 as a common regulator of
the MMPs and their inhibitors in a breast cancer cell
model, we treated the highly invasive MDA-MB-231 cell
line with different concentrations (0, 1, 5 or 10 ng/mL)
of recombinant TGF-b1 for 20 h. The mRNA expression
levels of PAI-I, a well-known TGF-b1 transcriptional
target, was used as a positive control for the MDA-MB-
231 treatment with this cytokine. As expected, we found
a greater than 10-fold increase in PAI-I expression in
TGF-b1-treated cells relative to untreated controls
(Additional file 1) for all TGF-b1 concentrations tested,
confirming that this cell line was still responsive to
TGF-b1 treatment. Upon treatment with TGF-b1, the
MDA-MB-231 cell line showed significantly increased
mRNA expression levels of MMPs (MMP-2, MMP-9
and MMP-14) and MMP inhibitors (TIMP-2 and
RECK) (Figure 3). The mRNA expression of MMP-2
was significantly upregulated in MDA-MB-231 cells
upon treatment with 1 ng/mL (p < 0.05) and 10 ng/mL
(p < 0.05) of TGF-b1, relative to the untreated control
cultures. Statistically significant increased transcriptional
expression levels of MMP-9 were verified upon treat-
ment of these cells with 1 ng/mL (p < 0.05) and 5 ng/
mL (p < 0.01) of recombinant TGF-b1. The MMP-14
mRNA levels were also significantly increased in the
MDA-MB-231 cells upon treatment with 1 ng/mL (p <
0.05) and 10 ng/mL (p < 0.05) of TGF-b1. The mRNA
expression levels of the MMP inhibitors were also upre-
gulated in TGF-b1-treated MDA-MB-231 cells (Figure
3). TIMP-2 expression levels were higher in MDA-MB-
Figure 2 Relative mRNA expression levels of TGF-b isoforms and receptors in breast cancer cell lines. Total RNA from a panel of five
human breast cancer cell lines displaying different invasion and metastatic potentiasl were used to analyze the mRNA expression levels of TGF-b
isoforms (TGF-b1, TGF-b2 and TGF-b3) and TGF-b receptors (TbRI and TbRII) by qRT-PCR. Results are presented as means ± standard errors from
three independent experiments, each measured in triplicate. *, p < 0.05, **, p < 0.01 and *** p < 0.001, all versus control (MCF-7).
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231 cells treated with 1 ng/mL (p < 0.05) and 5 ng/mL
(p < 0.05) of TGF-b1 than in the untreated ones. Simi-
larly, cells treated with 5 ng/mL (p < 0.05) and 10 ng/
mL (p < 0.001) of this cytokine displayed higher RECK
mRNA levels than untreated cultures (Figure 3).
The treatment with recombinant TGF-b1 was also
able to increase the protein levels of MMP-2, MMP-9
and TIMP-2, but downregulated RECK protein levels
(Figure 3). By Zymography assays, we verified that the
active MMP-2 (p < 0.01) and the pro-enzyme MMP-9
(p < 0.05) levels were significantly increased in MDA-
MB-231 upon treatment with 10 ng/mL of TGF-b1,
relative to the untreated condition. Like MMPs, TIMP-2
protein levels were also significantly (p < 0.05) increased
in MDA-MB-231 cells treated with the highest TGF-b1
concentration tested. Conversely, RECK protein levels
were decreased in TGF-b1-treated MDA-MB-231 cells.
This TGF-b1-mediated downregulation of RECK protein
levels was statistically significant at 5 ng/mL (p < 0.05)
treatment conditions (Figure 3). Altogether, these results
support that TGF-b1 modulates the mRNA and protein
levels of MMPs (MMP-2 and MMP-9) as much as their
inhibitors (TIMP-2 and RECK) in a dose-dependent
manner.
Figure 3 Relative mRNA and protein expression levels of MMPs and MMPs inhibitors in the MDA-MB-231 cell line treated with
different concentrations of TGF-b1. The mRNA expression levels of MMPs (MMP-2, MMP-9 and MMP-14) and MMPs inhibitors (TIMP-1, TIMP-2,
TIMP-3 and RECK) were analyzed by qRT-PCR using the total RNA from the MDA-MB-231 cells treated with 0, 1, 5 or 10 ng/mL TGF-b1 for 20 h.
The levels of pro-enzyme and active MMP-2 and MMP-9 proteins were evaluated by zymography. Total protein lysates were used to measure
the protein expression levels of MMP-14 and RECK by Western Blotting. The b-tubulin levels were used as protein loading control for Western
Blot analysis. Conditioned medium was used to analyze the protein levels of TIMPs (TIMP-1, TIMP-2 and TIMP-3) by Western blotting. The results
are presented in graphics as means ± standard errors from three independent experiments. The Western-blotting figures are representative of
one experiment. *, p < 0.05, **, p < 0.01 and *** p < 0.001, all versus control (untreated cell).
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In order to obtain direct evidence of the role of TGF-
b1 on modulation of the expression of MMPs and their
inhibitors, a “loss of function” study was pursued. To
this end, the endogenous TGF-b1 activity of the MDA-
MB-231 cell line was inhibited by using a specific anti-
body for neutralization of this cytokine. The MDA-MB-
231 cells were treated with different concentrations (0,
1, 10, 25 or 50 ng/mL) of anti-TGF-b1 antibody for 24
h. As shown in the Additional File 1, the efficiency of
TGF-b1 activity blockage was confirmed, since the
mRNA levels of PAI-I, a well known TGF-b1 target, sig-
nificantly decreased (p < 0.01) in cells subjected to
higher antibody concentrations (25 and 50 ng/mL). Sub-
sequently, the effect of TGF-b1 inhibition in the expres-
sion levels of MMPs and MMP inhibitors was assessed.
The results, shown in Figure 4, demonstrated that treat-
ment with the anti-TGF-b1 antibody was able to signifi-
cantly inhibit (p < 0.001) the mRNA expression levels of
MMP-2, MMP-9, TIMP-2 and RECK in MDA-MB-231
cells.
TGF-b1 induces ERK1/2 and p38 MAPK phosphorylation
with distinct kinetics
To explore the role of ERK1/2 and p38 MAPK pathways
in this proposed mechanism, we tested whether TGF-b1
is able to induce phosphorylation of these signal
transduction proteins. Total protein extracts were
obtained from MDA-MB-231 cells treated with 10 ng/
mL of TGF-b1 for different periods of time (0, 5 min,
10 min, 20 min, 30 min, 45 min, 1 h, 2 h and 3 h) and
the levels of ERK1/2 and p38 MAPK activation were
analyzed by Western Blotting. As shown in Figure 5,
TGF-b1 treatment induced a significant phosphorylation
(p < 0.05) of both ERK1/2 as well as p38 MAPK. We
also observed that these MAPKs showed two activation
peaks. The first one was reached shortly after TGF-b1
addition (10 min and 30 min for p-ERK1/2 and p-p38
MAPK, respectively) while the second one was achieved
after longer periods of time of treatment with this cyto-
kine (1 h for p-p38 MAPK).
Inhibition of ERK1/2 blocks TGF-b1-mediated
upregulation of MMP-9 and TIMP-2 and increases the
level of RECK protein
The role of ERK1/2 pathway in TGF-b1-mediated regula-
tion of MMPs and MMP inhibitors was also evaluated.
Different concentrations (0, 5, 10 or 20 μM) of an ERK1/
2 pharmacological inhibitor (PD98059) were used to pre-
treat MDA-MB-231 cells for 1 h. These cultures were
further stimulated with 10 ng/mL of TGF-b1 for 20 h. By
qRT-PCR, we found that the ERK1/2 inhibitor did not
affect the TGF-b1-mediated induction of MMP-2, MMP-
9, TIMP-2 and RECK mRNA expression mediated by
TGF-b1 treatment (Figure 6). However, the highest con-
centration of PD98059 significantly decreased (p < 0.001)
the amount of MMP-9 and TIMP-2 protein levels follow-
ing TGF-b1 treatment. ERK1/2 inhibition not only
blocked the TGF-b1-mediated downregulation of RECK
protein production, but also significantly increased RECK
mRNA expression. Cells treated with 20 μM of PD98059
and 10 ng/mL of TGF-b1 presented significantly higher
expression of RECK relative to cells treated with vehicle
(p < 0.05) or with TGF-b1 only (p < 0.001) (Figure 6).
These results suggest that the ERK1/2 activity is essential
for the modulation of MMP-9, TIMP-2 and RECK
expression by TGF-b1.
p38 MAPK inhibition blocked the TGF-b1-mediated
increase in MMP-2 and TIMP-2 protein levels
The role of p38 MAPK in the proposed TGF-b1-mediated
mechanism was also investigated. MDA-MB-231 cells
were pre-treated for 1 h with 0, 5, 10 or 20 μM of
SB203680 (a p38 MAPK pharmacological inhibitor) fol-
lowed by treatment with TGF-b1 (10 ng/mL). Inhibition
of p38 MAPK pathway significantly blocked (p < 0.05) the
TGF-b1-induced upregulation of MMP-2, MMP-9, TIMP-
2 and RECK mRNA levels. Interestingly, lower concentra-
tions of p38 MAPK inhibitor were required to abrogate
the action of TGF-b1 on mRNA levels of MMPs inhibitors
(TIMP-2 and RECK) (Figure 7).
Figure 4 Analysis of the effect of TGF-b1 loss of function on
the expression levels of MMPs and MMPs inhibitors by the
MDA-MB-231 cell line upon treatment with a neutralizing anti-
TGF-b1 antibody. The mRNA expression levels of MMPs (MMP-2,
MMP-9) and MMPs inhibitors (TIMP-2 and RECK) were analyzed by
qRT-PCR using total RNA from MDA-MB-231 cells treated for 24 h
with 0, 1, 10, 25 or 50 ng/mL of a specific neutralizing antibody to
the endogenous TGF-b1 bioactivity. The results are presented as
means ± standard errors from two independent experiments. **, p
< 0.01 and *** p < 0.001, all versus control (untreated cell).
Gomes et al. BMC Cancer 2012, 12:26
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The highest SB203680 concentration tested was able
to significantly (p < 0.05) inhibit the TGF-b1-mediated
induction of the active MMP-2 and TIMP-2 protein
levels (Figure 7). On the other hand, inhibition of p38
MAPK did not have a significant effect on MMP-9 pro-
tein induction or RECK protein downregulation pro-
moted by TGF-b1 treatment. Together, these data led
us to propose that p38 MAPK was responsible for the
mediation of the TGF-b1 effect on the MMP-2 and
TIMP-2 protein levels. It is important to note that
unlike ERK1/2 pathway, p38 MAPK activity was not
relevant for the TGF-b1 modulation of MMP-9 and
RECK expression.
ERK1/2 and p38 MAPK pathways crosstalk in the MDA-
MB-231 cellular model
The above results indicated that ERK1/2 and p38 MAPK
pathways were involved in the TGF-b1-mediated regula-
tion of MMPs and their inhibitors. Therefore, we inves-
tigated whether these signal transduction molecules
could crosstalk in MDA-MB-231 cells upon activation
by TGF-b1. To this end, MDA-MB-231 cells were pre-
treated with 20 μM of an ERK1/2 or p38 MAPK inhibi-
tor (PD98059 and SB203680, respectively) for 1 h and
then stimulated with 10 ng/mL of TGF-b1. Since ERK1/
2 and p38 MAPK displayed a different activation
kinetics, upon the cellular pre-treatment with PD98059
or SB203680, we performed TGF-b1 stimulation for per-
iods of times corresponding to the maximal activation of
each MAPK observed in the previous experiments
(Figure 5). Therefore, in addition to TGF-b1, cells were
treated with ERK1/2 inhibitor for 10 min and 3 h and
with the SB203680 for 30 min and 1 h.
TGF-b1 stimulation of MDA-MB-231 cells for 3 h did
not affect p38 MAPK activation (Figure 8A). However,
the levels of p-p38 MAPK were significantly higher (p <
0.05) in cells pre-treated with PD98059 relative to cells
treated only with TGF-b1 for the longest period of time.
Addition of TGF-b1 did not induce a significant change
on p-p38MAPK accumulation in ERK 1/2 inhibited cells
(Figure 8A). However, treatment with SB203680 pro-
moted a similar effect on p-ERK1/2 levels for 30 min of
treatment (Figure 8B). TGF-b1-treated cells had signifi-
cantly lower p-ERK1/2 protein (p < 0.001) when com-
pared with MDA-MB-231 cells pre-treated with the p38
MAPK specific inhibitor (Figure 8B). These results sug-
gest that the ERK1/2 and p38 MAPK pathways crosstalk
in the MDA-MB-231 cell model. However, TGF-b1 was
apparently not involved in this signalling interaction.
TGF-b1-increased migration and invasion capacities of
MDA-MB-231 cells are dependent on ERK1/2, p38 MAPK
and MMPs activities
Our results support the hypothesis that TGF-b1 is a com-
mon regulator of molecules classically related to cell moti-
lity and invasive phenotype. Thus, we examined the effect
of this cytokine on the migratory and invasive potential of
MDA-MB-231 cells. TGF-b1-treated MDA-MB-231 cells
presented a significantly increased (p < 0.001) migration
(Figure 9A) and invasion (Figure 9B) capacities, doubling
Figure 5 Kinetics profile of phospho-ERK1/2 and phospho-p38 MAPK proteins in MDA-MB-231 cell line treated with TGF-b1. Total
protein lysates from the MDA-MB-231 cells treated with 10 ng/mL of TGF-b1 for different periods of time (0, 5 min, 10 min, 20 min, 30 min, 45
min, 1 h, 2 h and 3 h) were used to analyze the protein levels of total and phosphorylated forms of ERK1/2 and p38 MAPK by Western blotting.
These results were analyzed and used to calculate the p-ERK1/2/total ERK1/2 and p-p38 MAPK/total p38 MAPK ratios during the kinetic of MDA-
MB-231 treatment with TGF-b1. The results are presented in graphics as means ± standard errors from three independent experiments. The
Western blotting figures are representative of one experiment. *, p < 0.05, ** and p < 0.01, all versus control (untreated cell).
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the number of cells present at the bottom of transwells.
Moreover, we investigated whether ERK1/2, p38 MAPK
and MMPs could act as mediators of this TGF-b1-
mediated effect in MDA-MB-231 motility. To this end,
cells were pre-treated for 1 h with 20 μM of either
PD98059 or SB203680, or with 40 μM of GM6001 (a
broad-spectrum MMPs inhibitor), and then stimulated
with 10 ng/mL TGF-b1. Treatment of the MDA-MB-231
cell line only with ERK1/2, p38 MAPK or MMPs inhibi-
tors did not have a significant effect in the migratory and
invasive phenotype in relation to cells treated with vehicle
(DMSO). However, all of these inhibitors were able to sig-
nificantly block (p < 0.001) the TGF-b1-induced migration
and invasion potential of MDA-MB-231 cells, suggesting
that TGF-b1 indeed utilizes ERK1/2 and p38 MAPK to
mediate the upregulation of MMPs.
Discussion
Metastasis is the final stage in tumor progression, being
the main factor associated with cancer-promoted deaths
Figure 6 Relative mRNA and protein expression of MMPs and MMPs inhibitors in MDA-MB-231 cells treated with TGF-b1 and an
ERK1/2 inhibitor. MDA-MB-231 cells were pre-treated for 1 h with different concentrations (0, 5, 10 or 20 μM) of PD98059 (ERK1/2
pharmacological inhibitor) and then stimulated with 10 ng/mL TGF-b1 by 20 h. Total RNA from these samples was used to analyze the mRNA
expression levels of MMPs (MMP-2 and MMP-9) and MMPs inhibitors (TIMP-2 and RECK) by qRT-PCR. The levels of pro-enzyme and active MMP-2
and MMP-9 proteins were evaluated by zymography. Total protein lysates were used to measure the protein expression levels of RECK by
Western blotting. The GAPDH protein expression was used as the loading control in Western blotting assays. Conditioned medium from these
cultures were also utilized to analyze the TIMP-2 protein levels by Western blotting. Results are presented in graphics as means ± standard errors
from three independent experiments. The Western blotting figures are representative of one experiment. For mRNA expression levels fold
change: MMP-2 (a versus c: p < 0.05, a versus d: p < 0.01, a versus e, f: p < 0.001), MMP-9 (a versus c, d, f: p < 0.01), TIMP-2 (a versus b: p < 0.01,
a versus c: p < 0.05, a versus d, e, f: p < 0.001) and RECK (a versus b, c: p < 0.05, a versus d, e, f: p < 0.001). For protein expression levels fold
change: MMP-2 (a versus c: p < 0.01, a versus d, e: p < 0.05), MMP-9 (a versus c: p < 0.001, c versus f: p < 0.001), TIMP-2 (a versus c: p < 0.01, c
versus f: p < 0.001) and RECK (a versus c: p < 0.01, a versus f: p < 0.05, c versus e, f:: p < 0.001).
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[42]. The balance between the activities of MMPs and
MMP inhibitors is the essential regulator of ECM degra-
dation and, consequently, of cellular phenotypes related
to motile and invasive capacities. Similar to other cancer
types, the breast cancer progression process is positively
correlated with increased MMPs and MMP inhibitors
expression and activity [12], suggesting a coordinate reg-
ulation mechanism. In this report, we demonstrated, for
the first time, that TGF-b1 is able to modulate MMP,
TIMP and RECK expression in MDA-MB-231 human
breast cancer cell line through ERK1/2 and p38MAPK.
Both of these transducer pathways were essential to the
TGF-b1-enhanced migration and invasion phenotypes;
however, each mediated the TGF-b1 signal for MMPs
and their inhibitors in a specific manner.
The important role of TGF-b during multiple stages of
cancer progression has been widely reported. However,
the status of several members of this pathway in human
cancers remains quite complex and unclear [43,44]. The
TGF-b receptors and their downstream transducers are
Figure 7 Relative mRNA and protein levels of MMPs and MMPs inhibitors in MDA-MB-231 cells treated with TGF-b1 and a p38 MAPK
inhibitor. MDA-MB-231 cells were pre-treated for 1 h with different concentrations (0, 5, 10 or 20 μM) of SB203680 (p38 MAPK pharmacological
inhibitor) and then stimulated with 10 ng/mL TGF-b1 by 20 h. Total RNA from these samples was used to analyze the mRNA expression levels of
MMPs (MMP-2 and MMP-9) and MMPs inhibitors (TIMP-2 and RECK) by qRT-PCR. The levels of pro-enzyme and active MMP-2 and MMP-9
proteins were evaluated by zymography. Total protein lysates were used to measure the protein levels of RECK by Western blotting. GAPDH
protein was used as the loading control in Western blotting assays. Conditioned medium from these cultures were also used to analyze the
TIMP-2 protein levels by Western blotting. Results are presented in graphics as means ± standard errors from three independent experiments.
The Western blotting figures are representative of one experiment. For mRNA expression levels fold change: MMP-2 (a versus c: p < 0.05, c
versus f: p < 0.05), MMP-9 (a versus c: p < 0.001, a versus d: p < 0.05, c versus f: p < 0.01), TIMP-2 (c versus e: p < 0.05, c versus f: p < 0.001) and
RECK (a versus c: p < 0.01, c versus e: p < 0.05, c versus f: p < 0.001). For protein expression levels fold change: MMP-2 (a versus c: p < 0.01, c
versus f: p < 0.05), MMP-9 (a versus c: p < 0.001, a versus d: p < 0.05), TIMP-2 (a versus c: p < 0.05, c versus f: p < 0.05) and RECK (a versus c, e, f:
p < 0.001, a versus d: p < 0.05).
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frequently lost, mutated or attenuated in human carci-
nomas, including pancreatic, colon and gastric tumors
[43,44]. Alternatively, other tumor types, such as breast
tumors, present much lower mutation frequency in
these TGF-b signaling effectors, but display many altera-
tions in their expression levels [43,45,46]. Only few
reports addressed more than one TGF-b pathway mem-
ber at the same time. Due to the lack of information
regarding profile complexity of the TGF-b network ele-
ments and their dependence on the cell context, we first
performed a general characterization of the TGF-b iso-
forms and their receptors by mRNA expression analysis
in a panel of five human breast cancer cell lines display-
ing diverse invasive and metastatic capacities. We
showed that, similar to MMPs, TIMPs and RECK, the
mRNA levels of TGF-b receptors I and II, are expressed
at a higher level in the most aggressive cell line, as com-
pared to the less invasive ones, except for TbRI that was
also highly expressed in ZR-75-1 cells. These results
corroborate prior reports in the literature from tumor
tissue samples, showing that, in breast cancer models,
TGF-b signaling appears to be correlated with tumor-
promoting functions [23,47,48].
TGF-b1 acts as a growth inhibitor at the early stages
of tumorigenesis while it stimulates EMT, tumor inva-
sion and metastasis in advanced tumors [40,41]. There-
fore, cancer cells in different stages of aggressiveness
respond differently to TGF-b treatment. The least inva-
sive (MCF-7) and the highly invasive (MDA-MB-231)
human breast cancer cell lines are examples of this dual
role of TGF-b. In this case, loss of estrogen receptor
expression and ras gene amplification, two very
common alterations during breast cancer progression,
are some factors involved in switching the phenotypic
response of TGF-b treatment, from anti-proliferative to
invasive [32]. Thus, TGF-b1 is not able to regulate pro-
liferation of the MDA-MB-231 cells [28,49]. However,
we demonstrate that this cytokine is a positive modula-
tor of migration and invasive potential of these cells.
Previous reports have suggested a crucial function of
TGF-b1 in cell motility control, some of which relate
this altered phenotype to its role as a modulator of
MMPs [23-27,50]. Kim and collaborators suggested that
TGF-b1 also induces invasion in pre-malignant breast
cancer cells (MCF10A), by upregulation of MMP-2 and
MMP-9 [21]. Subsequent reports also indicated that
MMP-2 and MMP-9 are essential in the TGF-b1-incre-
sead invasion of MCF10 cell series in a 3D model [23].
Similarly, the high motility phenotype presented by
TGF-b1-treated MDA-MB-231 cells was associated with
the upregulation of MMP-9 by this cytokine [50,51]. On
the other hand, in the MDA-MB-435 cell line, MMP-14
was shown to be the molecule responsible for the TGF-
b1-increased migration capacity [22]. However, none of
these previous reports investigated whether TGF-b1 can
also modulate the expression of MMP inhibitors, and
whether these inhibitors, thought to downmodulate
ECM breakdown, are also implicated in the TGF-b1-
induced cell spreading. Since the balance between
MMPs and their inhibitors is an important factor for
ECM degradation, the identification of common regula-
tors of MMPs, TIMPs and RECK is necessary to identify
the principal factors involved in the metastatic process.
Here we describe, for the first time, a molecular
Figure 8 Phosphorylated and total protein expression levels of p38 MAPK and ERK1/2 in MDA-MB-231 cell line treated with specific
inhibitors for these MAPKs and stimulated with TGF-b1 for different periods of time. (A) MDA-MB-231 cells were pre-treated with 20 μM
of PD98059 (specific ERK1/2 pharmacological inhibitor) for 1 h and then stimulated with 10 ng/mL TGF-b1 for different periods of time (0, 10
min and 3 h). Total protein lysates from these samples were used to analyze the protein expression levels of total and phosphorylated forms of
p38 MAPK by Western blotting. (B) The phosphorylated and total protein expression levels of ERK 1/2 were measured by Western blotting in
MDA-MB-231 cells pre-treated with 20 μM of SB203680 (p38 MAPK pharmacological specific inhibitor) for 1 h and stimulated with 10 ng/mL
TGF-b1 for 0, 30 min and 1 h. These results were analyzed and used to calculate the p-p38 MAPK/total p38 MAPK and p-ERK1/2/total ERK1/2
ratios, respectively. Results are presented in graphics as mean ± standard errors from three independent experiments. The Western blotting
figures are representative of one experiment. *, p < 0.05, *** and p < 0.001, all versus control (cells treated with DMSO, vehicle).
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mechanism in which TGF-b1 modulates MMP-2 and
MMP-9 as well as TIMP-2 and RECK expression. The
regulation of these MMPs inhibitors expression could
be related to a cellular response for reestablishment of
the proteases/inhibitors balance during cancer
progression.
We found some discrepancy between the mRNA and
protein expression levels of some MMPs and MMPs
inhibitors upon treatment with TGF-b1. For instance,
while RECK was increased at the transcriptional level,
its protein expression levels were inhibited by this cyto-
kine. This divergence could be due to the influence of
TGF-b1 in RECK mRNA and protein stability and
degradation rates and/or to other post-transcriptional
and post-translational molecular mechanisms.
Although mounting evidence supports the potential
role of RECK as a molecular marker for cancer prog-
nosis and controller of cellular metastatic capacity, no
reports are available unveiling its function in breast can-
cer [18,19]. For the first time, we have demonstrated
that expression of this membrane-associated MMP inhi-
bitor is regulated by TGF-b1 in a breast cancer cell cul-
ture model, suggesting that RECK could be involved in
the molecular mechanisms of breast cancer progression.
TGF-b1 is able to signal through both Smad-depen-
dent and Smad-independent mechanisms. However, pre-
vious evidences have established that each of these
pathways is related to distinct cellular responses to
TGF-b1 [35,52]. Therefore, the switching of TGF-b’s
role from a tumor suppressor to a pro-oncogenic-factor
during cancer progression could be caused by changes
in the way that this cytokine modulates its downstream
pathways. It has been suggested that Smads are involved
in the anti-tumor process, such as inhibition of cell pro-
liferation, while the Smad-independent pathways have
been implicated in induction of tumor progression
[35,52].
Here we analyzed the involvement of ERK1/2 and p38
MAPK, two well established Smad-independent path-
ways, in the proposed mechanism of coordinate regula-
tion of MMPs, TIMPs and RECK by TGF-b1 in breast
cancer cell lines. Our results demonstrate that both
MAPKs are important for this mechanism, each being
responsible for modulating specific molecules (Figure
10). Unlike previously reported data of MCF10A cells
[21], p38 MAPK as well as ERK1/2 were shown to be
key components mediating the TGF-b1-induced MMPs
upregulation. However, our data show that p38 MAPK
mediates increased levels of MMP-2 and ERK1/2 are
involved in the modulation of MMP-9 levels. Although
both p38 MAPK and ERK1/2 were required for TGF-b1
induction of the TIMP-2 protein expression, we demon-
strated that only ERK1/2 are responsible for the RECK
downregulation induced upon TGF-b1 treatment [21].
Conclusions
Taken together, the results obtained demonstrate that
TGF-b1 is a common regulator of MMPs (MMP-2 and
MMP-9) and their inhibitors (TIMP-2 and RECK) in
Figure 9 In vitro migration (A) and invasion (B) capacities of
the MDA-MB-231 cell line upon treatment with TGF-b1 and
inhibitors of ERK1/2, p38 MAPK and MMPs. MDA-MB-231 cells
were pre-treated for 1 h with 20 μM of either PD98059 or SB203680
(ERK1/2 and p38 MAPK pharmacological inhibitor, respectively) or
with 40 μM of GM6001 (a broad-spectrum MMPs inhibitor). After
the inhibition treatment these cells were stimulated with 10 ng/mL
TGF-b1 and allowed to migrate through uncoated transwells for 8 h
(A) or invade through matrigel-coated transwells for 24 h (B). The
number of cells at the bottom of the transwell filters was counted
at the end of each assay. Results are presented as means ±
standard errors from three independent experiments, performed in
duplicate, all versus control (cells treated with DMSO, vehicle).
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breast cancer cell models. Besides TGF-b1 function in
controlling extracellular matrix components synthesis
[53], our results provide important evidence that this
cytokine performs a central and intricate function in the
control of the ECM status by the modulation of MMPs,
TIMPs and RECK expression. Subsequent in vivo assays
should be performed to further support our data. The
TGF-b1-mediated balance among these proteases and
their specific inhibitors seems to be a result of the equi-
librium between p38 MAPK and ERK1/2 activities (Fig-
ure 10). The crosstalk between the MAPK pathways
shown here could also increase the complexity of this
TGF-b1 effect on cancer cells. Furthermore, the dose-
dependent TGF-b1 functions on MMP-9 and RECK
protein levels emphasize the multifaceted mechanism of
this cytokine in the control of tumor invasion and meta-
static capacities. Thus, the promising application of clin-
ical approaches based on TGF-b1 targeting for breast
cancer treatment may be very challenging, due to the
complex and broad-spectrum actions of this cytokine in
cancer progression and microenvironment architecture.
Additional material
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b1 antibody for 24 h. The results are presented as means ± standard
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